Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: Harvard Business Publishing
Published in: 2001

Abstract

Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian pharmaceutical firm, Cipla, that it would copy U.S. firms'' AIDS drugs and sell them at cost to countries in Africa. Made up of excerpts from 10 articles and highlights the intense feelings on both sides of the issue. Encourages students to think about the short- and long-term consequences of various approaches, the role of government and international institutions, and the pressures facing drug company executives.

About

Abstract

Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian pharmaceutical firm, Cipla, that it would copy U.S. firms'' AIDS drugs and sell them at cost to countries in Africa. Made up of excerpts from 10 articles and highlights the intense feelings on both sides of the issue. Encourages students to think about the short- and long-term consequences of various approaches, the role of government and international institutions, and the pressures facing drug company executives.

Related